48 related articles for article (PubMed ID: 8750055)
1. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
3. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
[TBL] [Abstract][Full Text] [Related]
4. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.
Staats HF; Kirwan SM; Whisnant CC; Stephenson JL; Wagener DK; Majumder PP
Clin Vaccine Immunol; 2010 Mar; 17(3):412-9. PubMed ID: 20107010
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
[TBL] [Abstract][Full Text] [Related]
6. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report.
Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
BMC Pediatr; 2020 Oct; 20(1):480. PubMed ID: 33059607
[TBL] [Abstract][Full Text] [Related]
7. The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.
Marshall JL; Flores-Langarica A; Kingsley RA; Hitchcock JR; Ross EA; López-Macías C; Lakey J; Martin LB; Toellner KM; MacLennan CA; MacLennan IC; Henderson IR; Dougan G; Cunningham AF
J Immunol; 2012 Dec; 189(12):5527-32. PubMed ID: 23162127
[TBL] [Abstract][Full Text] [Related]
8. Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi.
Acevedo R; Callicó A; Aranguren Y; Zayas C; Valdés Y; Pérez O; García L; Ferro VA; Pérez JL
BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S10. PubMed ID: 23458379
[TBL] [Abstract][Full Text] [Related]
9. Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Bijukchhe SM; Gurung M; Pokhrel B; Shakya M; Pant D; Maskey P; Maskey H; Dhakal B; Rajkarkinar S; Bista S; Voysey M; Mujadidi YF; Kim YC; Atherton R; Jones E; Mclean F; Shrestha S; Hill M; Nyland KT; Kelly S; O'reilly P; Sah GP; Basnyat B; Pollard AJ; Shrestha S
Vaccine; 2024 Mar; 42(8):2018-2025. PubMed ID: 38395723
[TBL] [Abstract][Full Text] [Related]
10. A description of a pre-emptive typhoid Vi capsular polysaccharide vaccination campaign after the 2015 earthquake in Nepal and vaccine effectiveness evaluation.
Dhoubhadel BG; Sawada I; Shrestha D; Fukuya Y; Raya GB; Nébié EI; Hayashi Y; Pasakhala R; Suzuki M; Morimoto K; Parry CM; Ariyoshi K
Trop Med Health; 2024 Jan; 52(1):14. PubMed ID: 38281965
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of vaccine-induced antibody responses: impact of new technologies.
Zaccaro DJ; Wagener DK; Whisnant CC; Staats HF
Vaccine; 2013 Jun; 31(25):2756-61. PubMed ID: 23583812
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis.
Hale C; Bowe F; Pickard D; Clare S; Haeuw JF; Powers U; Menager N; Mastroeni P; Dougan G
Vaccine; 2006 May; 24(20):4312-20. PubMed ID: 16600446
[TBL] [Abstract][Full Text] [Related]
13. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea.
Lim SM; Jung HS; Kim MJ; Park DW; Kim WJ; Cheong HJ; Park SC; Lee KC; Shin YK; Tan HK; Kim SL; Sohn JW
J Microbiol Biotechnol; 2007 Apr; 17(4):611-5. PubMed ID: 18051272
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
16. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
Robbins JD; Robbins JB
J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
[TBL] [Abstract][Full Text] [Related]
17. A new typhoid vaccine composed of the Vi capsular polysaccharide.
Plotkin SA; Bouveret-Le Cam N
Arch Intern Med; 1995 Nov; 155(21):2293-9. PubMed ID: 7487253
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
